Outpace Bio raises $30m led by Artis Ventures, Lyell

The Seattle-based company raises funding from in an oversubscribed round led by Artis Ventures and Lyell Immunopharma.

To view this content, you need to sign in.

You should only be asked to sign in once. Not the case? Click here

Register now to access this content and more for free.

Share this